Navigation Links
UCI Professor Zhibin Guan Joins NuGene Advisory Board

IRVINE, Calif., March 30, 2015 /PRNewswire/ -- NuGene International, Inc. ("NuGene") (OTCQB: NUGN), announced today that its subsidiary corporation, NuGene BioPharma, Inc. has added another internationally recognized researcher to its advisory board.

Dr. Guan is an internationally recognized researcher in bio-inspired materials and bio-materials fields. After finishing his college education at Peking University, China, Professor Guan received his Ph.D. degree from the University of North Carolina, Chapel Hill. Following a postdoctoral training at the California Institute of Technology (Caltech), he spent five years working at the Central Research and Development Laboratory of DuPont as a Senior Research Scientist.

He became a faculty member with the Chemistry, Biomedical Engineering, and Chemical Engineering and Materials Science departments of the University of California, Irvine in 2000 and was promoted to full professor in 2006.

Professor Guan is recognized for his contributions to macromolecular chemistry, bio-inspired materials design, and functional bio-materials for tissue engineering and gene delivery. He is the author of more than 80 publications in peer-reviewed journals including Science, Nature Materials, Nature Biotechnology, Nature Chemistry, etc.

Dr. Guan is the inventor of more than a dozen patents, and his work has been cited by others over 5000 times. He has received numerous awards including the Humboldt Bessel Research Award, the Camille Dreyfus Teacher-Scholar Award, the NSF CAREER Award, and the Beckman Young Investigator Award. In 2008, he was elected a Fellow of the American Association for the Advancement of Science.

"We continue to attract and recruit special talents to our advisory board," stated NuGene International's CEO Ali Kharazmi when announcing the addition. "His knowledge of functional bio-materials for tissue engineering and gene delivery is a perfect fit with our current board of advisors. As we seek to advance the stem cell enhanced cosmeceutical and pharmacological fields, Dr. Guan's expertise in these areas will be critical."

About NuGene International, Inc.

NuGene International, Inc. specializes in developing, manufacturing and marketing proprietary regenerative cosmeceutical and pharmaceutical products based on adipose derived human stem cell and human stem cell media.  The US Department of Health and Human Services calls regenerative medicine the "next evolution of medical treatments".  The regenerative medical market which includes cosmeceuticals and pharmaceuticals was estimated at $7.2 Billion in the US in 2014 and is expected to rapidly grow in the coming years according to RNCOS Business Consultancy Services Global Cosmeceuticals Market report.  NuGene's cosmeceutical and pharmaceutical products are based on proprietary stem cell based regenerative formulations derived from non-controversial, adult human stem cell derived media obtained from adipose tissue.  NuGene's exclusive products combine its in-house advancements, proprietary technologies, and patent pending formulations.  The company has two patents pending covering 15 unique applications and inventions.  NuGene's goal is to leverage its extensive knowledge and expertise to develop age defying regenerative cosmeceutical skincare and hair care products in addition to pharmaceutical products based on the same regenerative science platform.

Forward-Looking Statements

This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the matters and transactions considered by NuGene International may not proceed as contemplated, and by all other matters and assumptions specified in NuGene's filings with the Securities and Exchange Commission, especially those risks and other matters described under "Risk Factors" within NuGene's Form 8-K filed with the Commission on January 6, 2015. These statements are made based upon current expectations that are subject to risk and uncertainty. NuGene does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information.

Investor/ Media Relations:
Chris Rosgen
Capital Market Relations

Logo -


SOURCE NuGene International, Inc.
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. Immunocore Appoints Professor Sir John Bell to its Board of Directors
2. Bioinformatics book by Waynesburg University professor published internationally
3. Professor Federico Rosei named to the Royal Society of Canada
4. Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain
5. UT Dallas professor receives Engineer of the Year award
6. John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva
7. American Physical Society names UT Arlington professor a fellow
8. Pioneer in Therapeutic Patient Education, Professor Jean-Philippe Assal, Wins 2013 IDF Europe Prize in Diabetes for Long-Standing Achievement
9. NJIT professor invents a flexible battery
10. Mainz University receives approval for an Alexander von Humboldt Professorship in Physics
11. Creabilis Appoints Professor Gil Yosipovitch and Professor Praveen Anand to its Scientific Advisory Board
Post Your Comments:
(Date:11/11/2018)... ... ... Triple W, an innovator of connected health devices, today announced that it ... ®, the first health tech wearable device for incontinence that monitors how full your ... announcement was made during CES Unveiled New York, an invite-only tech event bringing together ...
(Date:11/7/2018)... ... November 07, 2018 , ... Diversified Technologies, Inc. (DTI) ... the Arizona Center for Algae Technology and Innovation at ASU. Funded by a USDA ... for those involved with algal and predator control applications. , Algae ponds get up ...
(Date:11/5/2018)... ... November 05, 2018 , ... 2Blades ... Transcription Activator Like (TAL) effector code technology for applications in advancing research in ... technology in plants. Since its discovery in 2009, the efficacy of TAL effector-based DNA ...
(Date:10/31/2018)... POWAY, Calif. (PRWEB) , ... October 30, 2018 , ... Pippa Rose is a young ... was around one year old, Pippa suffered a partial tear to the cruciate ligament in ... unable to run or go on walks. Kinsley reported that it broke her heart ...
Breaking Biology Technology:
(Date:11/15/2018)... , ... November 14, 2018 , ... ... Jill Carnahan, MD, founder and medical director of Flatiron Functional Medicine to its ... the world, Dr. Carnahan will bring to uBiome extensive experience in treating the ...
(Date:11/14/2018)... ... November 14, 2018 , ... In recognition of World Diabetes Day, Diopsys ... and advocacy. The company is reaching out to help educate patients and the healthcare ... importance of vision testing for people with the disease. , The American Diabetes Association ...
(Date:11/13/2018)... LINDA, Calif. (PRWEB) , ... ... ... (HRAM) mass spectrometers (MS) are a class of MS instrumentation with capability ... measuring their accurate masses. Specifically, those coupled to liquid chromatograph (HRAM LC/MS) ...
Breaking Biology News(10 mins):